News
$Alzamend Neuro (ALZN.US)$ EXCLUSIVE: Alzamend Neuro Reveals Full Data Set From Multiple Ascending Dose Trial For Lead Candidate For Dementia Related to Alzheimer's
Benzinga· just
On Wednesday, Alzamend Neuro, Inc. (NASDAQ:ALZN) said it received the final full data set from its multiple ascending dose clinical trial for AL001 for dementia related to Alzheimer's. Preliminary results were released in June 2023.
Identified by an independent safety review committee, this MTD represents a pivotal step forward; it delivers lithium at a lithium carbonate equivalent dose of 240 mg, taken three times daily (TID).
The Phase 2A study evaluated the safety and tolerability of AL001 under multiple-dose, steady‐state conditions.
It determined the MTD in patients diagnosed with mild to moderate Alzheimer's disease and in healthy non-elderly and elderly subjects with adequate renal function.
Benzinga· just
On Wednesday, Alzamend Neuro, Inc. (NASDAQ:ALZN) said it received the final full data set from its multiple ascending dose clinical trial for AL001 for dementia related to Alzheimer's. Preliminary results were released in June 2023.
Identified by an independent safety review committee, this MTD represents a pivotal step forward; it delivers lithium at a lithium carbonate equivalent dose of 240 mg, taken three times daily (TID).
The Phase 2A study evaluated the safety and tolerability of AL001 under multiple-dose, steady‐state conditions.
It determined the MTD in patients diagnosed with mild to moderate Alzheimer's disease and in healthy non-elderly and elderly subjects with adequate renal function.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
